Pharmacologically induced erections among geriatric men.

Area of Science:

• Urology
• Geriatrics
• Sexual Medicine

Background:

• Erectile dysfunction (ED) significantly impacts the geriatric population.
• Current research on intracavernous injection therapy for ED primarily involves younger patient cohorts.
• Aging involves unique physical, psychological, and social changes affecting sexual health.

Purpose of the Study:

• To assess the safety and efficacy of intracavernous injection therapy in elderly men with ED.
• To compare treatment outcomes and complication rates between geriatric and younger patient groups.
• To characterize the profile of elderly men experiencing impotence.

Main Methods:

• Retrospective analysis of patients treated at a university medical center's male sexual dysfunction clinic.
• Comparison of 65 patients aged 65+ (mean age 70) with a younger cohort (mean age 47) receiving papaverine and phentolamine injections.
• Evaluation of impotence etiology, patient satisfaction, and complication rates.

Main Results:

• Significant differences in the etiology of erectile dysfunction were observed between the age groups.
• Treatment response rates were equivalent across both geriatric and younger cohorts.
• Elderly patients required higher papaverine and phentolamine dosages and used the medication less frequently.
• Complications were infrequent, minor, and occurred with similar frequency in both groups.

Conclusions:

• Intracavernous injection therapy with papaverine and phentolamine is a safe and effective treatment for erectile dysfunction in elderly men.
• The efficacy of this treatment is comparable between older and younger men, despite potential differences in dosage and usage frequency.
• This therapeutic approach offers a viable option for managing ED in the geriatric population.